Article Text

Download PDFPDF
Fingolimod significantly reduces MRI activity in paediatric-onset multiple sclerosis (MS)
  1. Laura Chapman
  1. Northern General Hospital, Sheffield, UK
  1. Correspondence to Dr Laura Chapman, Northern General Hospital, Sheffield S5 7AU, UK; laura.chapman38{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Study design: 2-year randomised, double-blind trial period and a 5-year extension phase in which all patients were treated with fingolimod.

Study question

Setting: 105 study locations worldwide.

Patients: 215 patients, 10–17 years of age with relapsing multiple sclerosis (MS) or who had evidence of one or more gadolinium-enhancing (Gd+) lesion on T1-weighted MRI within the 6 months prior to randomisation.

Intervention: oral fingolimod 0.5 mg per day or intramuscular interferon beta-1a (INF B-1a) at dose of 30 ug per week for up to 2 years, 1:1 allocation. …

View Full Text


  • Review of article Arnold DL, Banwell B, Bar-Or A et al. Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: Results from the phase 3 PARADIGMS study. J Neurol Neurosurg Psychiatry. 2020;91:483–92.

  • Twitter @laura24chapman

  • Provenance and peer review Not commissioned; internally peer reviewed.